针对携带BRCA1和BRCA2基因突变者的乳腺癌预防：他莫昔芬能发挥作用吗？ - Suppr

Suppr

超能文献

Breast cancer prevention for BRCA1 and BRCA2 mutation carriers: is there a role for tamoxifen?

作者信息

Phillips Kelly-Anne, Lindeman Geoffrey J

机构信息

Division of Cancer Medicine, Peter MacCallum Cancer Centre, Locked Bag 1, A'Beckett St, Victoria, 8006, Australia.

出版信息

Future Oncol. 2014 Mar;10(4):499-502. doi: 10.2217/fon.13.278.

DOI:10.2217/fon.13.278

PMID:24754577

Abstract

摘要

相似文献

Breast cancer prevention for BRCA1 and BRCA2 mutation carriers: is there a role for tamoxifen?

Future Oncol. 2014 Mar;10(4):499-502. doi: 10.2217/fon.13.278.

Prevention and management of hereditary breast cancer.

J Clin Oncol. 2005 Mar 10;23(8):1656-63. doi: 10.1200/JCO.2005.10.035.

Tamoxifen as chemoprevention in BRCA1 and BRCA2 mutation carriers with breast cancer: a pilot survey of physicians.

J Clin Oncol. 2003 Dec 1;21(23):4322-8. doi: 10.1200/JCO.2003.02.107.

The Role of Risk-Reducing Surgery in Hereditary Breast and Ovarian Cancer.

N Engl J Med. 2016 Feb 4;374(5):454-68. doi: 10.1056/NEJMra1503523.

Breast cancer prevention in high-risk women: searching for new options.

J Natl Cancer Inst. 2011 May 4;103(9):710-1. doi: 10.1093/jnci/djr159. Epub 2011 Apr 22.

BRCA1/BRCA2 mutation status and analysis of cancer family history in participants of the Royal Marsden Hospital tamoxifen chemoprevention trial.

Cancer Lett. 2007 Mar 18;247(2):259-65. doi: 10.1016/j.canlet.2006.05.003. Epub 2006 Jun 14.

Modifiers of risk of hereditary breast cancer.

Oncogene. 2006 Sep 25;25(43):5832-6. doi: 10.1038/sj.onc.1209870.

Chemoprevention options for BRCA1 and BRCA2 mutation carriers.

J Clin Oncol. 2000 Nov 1;18(21 Suppl):93S-9S.

Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers.

J Clin Oncol. 2013 Sep 1;31(25):3091-9. doi: 10.1200/JCO.2012.47.8313. Epub 2013 Aug 5.

Tamoxifen and risk of contralateral breast cancer among women with inherited mutations in BRCA1 and BRCA2: a meta-analysis.

Breast Cancer. 2015 Jul;22(4):327-34. doi: 10.1007/s12282-015-0619-6. Epub 2015 May 30.

引用本文的文献

Update on Adipose Tissue and Cancer.

Endocr Rev. 2023 Nov 9;44(6):961-974. doi: 10.1210/endrev/bnad015.

Treatment Patterns, Safety, and Patient Reported Outcomes among Adult Women with Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer with or without, or with Unknown, Mutation(s): Results of a Real-World Study from the United States, United Kingdom, and four EU Countries.

Breast Care (Basel). 2022 Oct;17(5):460-469. doi: 10.1159/000523970. Epub 2022 Mar 11.

Nonsurgical Prevention Strategies in and Mutation Carriers.

Breast Care (Basel). 2021 Apr;16(2):144-148. doi: 10.1159/000507503. Epub 2020 May 11.

RANK ligand as a potential target for breast cancer prevention in BRCA1-mutation carriers.

Nat Med. 2016 Aug;22(8):933-9. doi: 10.1038/nm.4118. Epub 2016 Jun 20.

Loss of the N-terminal methyltransferase NRMT1 increases sensitivity to DNA damage and promotes mammary oncogenesis.

Oncotarget. 2015 May 20;6(14):12248-63. doi: 10.18632/oncotarget.3653.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Breast cancer prevention for BRCA1 and BRCA2 mutation carriers: is there a role for tamoxifen?

作者信息

Phillips Kelly-Anne, Lindeman Geoffrey J

机构信息

Division of Cancer Medicine, Peter MacCallum Cancer Centre, Locked Bag 1, A'Beckett St, Victoria, 8006, Australia.

出版信息

Future Oncol. 2014 Mar;10(4):499-502. doi: 10.2217/fon.13.278.

DOI:10.2217/fon.13.278

PMID:24754577

Abstract

摘要

相似文献

Breast cancer prevention for BRCA1 and BRCA2 mutation carriers: is there a role for tamoxifen?

Future Oncol. 2014 Mar;10(4):499-502. doi: 10.2217/fon.13.278.

Prevention and management of hereditary breast cancer.

J Clin Oncol. 2005 Mar 10;23(8):1656-63. doi: 10.1200/JCO.2005.10.035.

Tamoxifen as chemoprevention in BRCA1 and BRCA2 mutation carriers with breast cancer: a pilot survey of physicians.

J Clin Oncol. 2003 Dec 1;21(23):4322-8. doi: 10.1200/JCO.2003.02.107.

The Role of Risk-Reducing Surgery in Hereditary Breast and Ovarian Cancer.

N Engl J Med. 2016 Feb 4;374(5):454-68. doi: 10.1056/NEJMra1503523.

Breast cancer prevention in high-risk women: searching for new options.

J Natl Cancer Inst. 2011 May 4;103(9):710-1. doi: 10.1093/jnci/djr159. Epub 2011 Apr 22.

BRCA1/BRCA2 mutation status and analysis of cancer family history in participants of the Royal Marsden Hospital tamoxifen chemoprevention trial.

Cancer Lett. 2007 Mar 18;247(2):259-65. doi: 10.1016/j.canlet.2006.05.003. Epub 2006 Jun 14.

Modifiers of risk of hereditary breast cancer.

Oncogene. 2006 Sep 25;25(43):5832-6. doi: 10.1038/sj.onc.1209870.

Chemoprevention options for BRCA1 and BRCA2 mutation carriers.

J Clin Oncol. 2000 Nov 1;18(21 Suppl):93S-9S.

Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers.

J Clin Oncol. 2013 Sep 1;31(25):3091-9. doi: 10.1200/JCO.2012.47.8313. Epub 2013 Aug 5.

Tamoxifen and risk of contralateral breast cancer among women with inherited mutations in BRCA1 and BRCA2: a meta-analysis.

Breast Cancer. 2015 Jul;22(4):327-34. doi: 10.1007/s12282-015-0619-6. Epub 2015 May 30.

引用本文的文献

Update on Adipose Tissue and Cancer.

Endocr Rev. 2023 Nov 9;44(6):961-974. doi: 10.1210/endrev/bnad015.

Breast Care (Basel). 2022 Oct;17(5):460-469. doi: 10.1159/000523970. Epub 2022 Mar 11.

Nonsurgical Prevention Strategies in and Mutation Carriers.

Breast Care (Basel). 2021 Apr;16(2):144-148. doi: 10.1159/000507503. Epub 2020 May 11.

RANK ligand as a potential target for breast cancer prevention in BRCA1-mutation carriers.

Nat Med. 2016 Aug;22(8):933-9. doi: 10.1038/nm.4118. Epub 2016 Jun 20.

Loss of the N-terminal methyltransferase NRMT1 increases sensitivity to DNA damage and promotes mammary oncogenesis.

Oncotarget. 2015 May 20;6(14):12248-63. doi: 10.18632/oncotarget.3653.